ARCT — Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc (ARCT) is a biotechnology company listed on NASDAQ. It is led by Joseph E. Payne M.Sc., based in 10628 Science Center Drive, San Diego, CA, United States, 92121, with about 174 employees. Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Latest reported ARCT revenue for 2025-09-30 was $17.2M. Net income was -$13.4M. Revenue was down 39.4% from 2025-06-30 to 2025-09-30. ARCT currently screens at market cap $369.4M.

Use this ARCT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ARCT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ARCT SEC filings page. Lician reads the product cache first so this HTML stays unique to Arcturus Therapeutics Holdings Inc even when a live quote feed is slow.